中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 12
Dec.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(12): 2548-2552

Comprehensive treatment of pancreatic cancer based on multidisciplinary diagnosis and treatment

DOI: 10.12449/JCH241229

  • Department of Hepatobiliary Surgery，Peking University People’s Hospital，Beijing 100044，China

Research funding:

Beijing Municipal Natural Science Foundation (7192212);

Chen Xiao-Ping Foundation for the Development of Science and Technology of Hubei Province-Clinical Research Special Fund (CXPJJH122002-061)

More Information
  • Corresponding author: LI Tao， litao3261@pkuph.edu.cn （ORCID： 0009-0001-2428-8104）
  • Received Date: 2024-03-27
  • Accepted Date: 2024-06-19
  • Published Date: 2024-12-25
    Abstract
  • Pancreatic cancer is a common malignant tumor of the digestive tract， and the incidence of pancreatic cancer has been gradually increasing in recent years. The main pathological types of pancreatic cancer include ductal adenocarcinoma， small gland carcinoma， and acinar cell carcinoma， among which duct adenocarcinoma is the most common pathological type. Multidisciplinary diagnosis and treatment （MDT） is a new diagnostic and therapeutic mode for pancreatic cancer， and different medical teams， including hepatobiliary surgery， gastroenterology， endocrinology， radiology， and radiotherapy， are gathered to discuss the conditions of patients and develop treatment regimens and subsequent management measures， so as to determine the optimal individualized treatment regimen. With the continuous clarification and development of the concept of precision therapy and the discovery of related gene mutations， promising prospects and individualized treatment have been achieved for the treatment of pancreatic cancer， thereby providing opportunities for improving the treatment outcome of patients. This article analyzes the interaction between different disciplines under the model of MDT， discusses the development trend and directions of the treatment regimens for pancreatic cancer， summarizes the current research work for pancreatic cancer， and proposes the future research directions for MDT in pancreatic cancer.

     

    • FullText(HTML)
  • loading
    • References(28)
  • [1]
    SIEGEL RL, MILLER KD, WAGLE NS, et al. Cancer statistics, 2023[J]. CA Cancer J Clin, 2023, 73( 1): 17- 48. DOI: 10.3322/caac.21763.
    [2]
    HAN B, ZHENG R, ZENG H, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4( 1): 47- 53. DOI: 10.1016/j.jncc.2024.01.006.
    [3]
    SHEN ZY, ZHANG J, ZHAO SW, et al. Preoperative biliary drainage of severely obstructive jaundiced patients decreases overall postoperative complications after pancreaticoduodenectomy: A retrospective and propensity score-matched analysis[J]. Pancreatology, 2020, 20( 3): 529- 536. DOI: 10.1016/j.pan.2020.02.002.
    [4]
    NEHME F, LEE JH. Preoperative biliary drainage for pancreatic cancer[J]. Dig Endosc, 2022, 34( 3): 428- 438. DOI: 10.1111/den.14081.
    [5]
    SHYR YM, WANG SE, CHEN SC, et al. Robotic pancreaticoduodenectomy in the era of minimally invasive surgery[J]. J Chin Med Assoc, 2020, 83( 7): 639- 643. DOI: 10.1097/JCMA.0000000000000333.
    [6]
    GENG XP. Debate between minimally invasive and open hepatopancreatobiliary surgery in the era of artificial intelligence[J]. Chin J Pract Surg, 2022, 42( 8): 845- 849. DOI: 10.19538/j.cjps.issn1005-2208.2022.08.02.

    耿小平. 人工智能时代肝胆胰外科微创技术与开放手术之争[J]. 中国实用外科杂志, 2022, 42( 8): 845- 849. DOI: 10.19538/j.cjps.issn1005-2208.2022.08.02.
    [7]
    VERSTEIJNE E, VOGEL JA, BESSELINK MG, et al. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer[J]. Br J Surg, 2018, 105( 8): 946- 958. DOI: 10.1002/bjs.10870.
    [8]
    General Office of National Health Commission. Standard for diagnosis and treatment of pancreatic cancer(2022 edition)[J]. J Clin Hepatol, 2022, 38( 5): 1006- 1015. DOI: 10.3969/j.issn.1001-5256.2022.05.007.

    国家卫生健康委办公厅. 胰腺癌诊疗指南(2022年版)[J]. 临床肝胆病杂志, 2022, 38( 5): 1006- 1015. DOI: 10.3969/j.issn.1001-5256.2022.05.007.
    [9]
    VERSTEIJNE E, van DAM JL, SUKER M, et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: Long-term results of the Dutch randomized PREOPANC trial[J]. J Clin Oncol, 2022, 40( 11): 1220- 1230. DOI: 10.1200/JCO.21.02233.
    [10]
    MA M, NIU TT, HAO Q, et al. Clinical analysis of stereotactic radiotherapy combined with concurrent chemoradiotherapy for pancreatic cancer[J]. Trauma Crit Care Med, 2022, 10( 5): 380- 381. DOI: 10.16048/j.issn.2095-5561.2022.05.18.

    马明, 牛婷婷, 郝倩, 等. 立体定向放射治疗联合同步放化疗治疗胰腺癌临床效果分析[J]. 创伤与急危重病医学, 2022, 10( 5): 380- 381. DOI: 10.16048/j.issn.2095-5561.2022.05.18.
    [11]
    PERRI G, MARCHEGIANI G, MALLEO G, et al. Neoadjuvant therapy in resectable pancreatic cancer-is this the way forward?-a narrative review[J]. Chin Clin Oncol, 2021, 10( 5): 47. DOI: 10.21037/cco-21-51.
    [12]
    MELISI D, ZECCHETTO C, MERZ V, et al. Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trial[J]. Eur J Cancer, 2024, 196: 113430. DOI: 10.1016/j.ejca.2023.113430.
    [13]
    TANG R, XU J, WANG W, et al. Targeting neoadjuvant chemotherapy-induced metabolic reprogramming in pancreatic cancer promotes anti-tumor immunity and chemo-response[J]. Cell Rep Med, 2023, 4( 10): 101234. DOI: 10.1016/j.xcrm.2023.101234.
    [14]
    KLEEFF J, KORC M, APTE M, et al. Pancreatic cancer[J]. Nat Rev Dis Primers, 2016, 2: 16022. DOI: 10.1038/nrdp.2016.22.
    [15]
    STOCKEN DD, BÜCHLER MW, DERVENIS C, et al. Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer[J]. Br J Cancer, 2005, 92( 8): 1372- 1381. DOI: 10.1038/sj.bjc.6602513.
    [16]
    TEMPERO MA, PELZER U, O’REILLY EM, et al. Adjuvant nab-paclitaxel+gemcitabine in resected pancreatic ductal adenocarcinoma: Results from a randomized, open-label, phase III trial[J]. J Clin Oncol, 2023, 41( 11): 2007- 2019. DOI: 10.1200/JCO.22.01134.
    [17]
    REDDY AV, HILL CS, SEHGAL S, et al. Stereotactic body radiation therapy for the treatment of locally recurrent pancreatic cancer after surgical resection[J]. J Gastrointest Oncol, 2022, 13( 3): 1402- 1412. DOI: 10.21037/jgo-22-38.
    [18]
    WAINBERG ZA, MELISI D, MACARULLA T, et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma(NAPOLI 3): A randomised, open-label, phase 3 trial[J]. Lancet, 2023, 402( 10409): 1272- 1281. DOI: 10.1016/S0140-6736(23)01366-1.
    [19]
    NCCN Guidelines Panel Disclosures. NCCN clinical practice guidelines in oncology-pancreatic adenocarcinoma[EB/OL].[ 2024-08-02]. http://www.nccn.org/patients. http://www.nccn.org/patients
    [20]
    JIN RT, HAN X, SUN ZQ, et al. Advances in the treatment of hepatic oligometastatic pancreatic cancer[J]. J Hepatopancreatobiliary Surg, 2022, 34( 10): 636- 641. DOI: 10.11952/j.issn.1007-1954.2022.10.013.

    金若棠, 韩鑫, 孙忠权, 等. 胰腺癌伴肝脏寡转移治疗进展[J]. 肝胆胰外科杂志, 2022, 34( 10): 636- 641. DOI: 10.11952/j.issn.1007-1954.2022.10.013.
    [21]
    MULLER M, TOUGERON D. KRAS G12C inhibitors: Also a new promising new targeted therapy in advanced pancreatic adenocarcinoma?[J]. Transl Cancer Res, 2023, 12( 12): 3227- 3232. DOI: 10.21037/tcr-23-1629.
    [22]
    STRICKLER JH, SATAKE H, GEORGE TJ, et al. Sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer[J]. N Engl J Med, 2023, 388( 1): 33- 43. DOI: 10.1056/NEJMoa2208470.
    [23]
    HALLIN J, BOWCUT V, CALINISAN A, et al. Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor[J]. Nat Med, 2022, 28( 10): 2171- 2182. DOI: 10.1038/s41591-022-02007-7.
    [24]
    HILMI M, DELAYE M, MUZZOLINI M, et al. The immunological landscape in pancreatic ductal adenocarcinoma and overcoming resistance to immunotherapy[J]. Lancet Gastroenterol Hepatol, 2023, 8( 12): 1129- 1142. DOI: 10.1016/S2468-1253(23)00207-8.
    [25]
    ROJAS LA, SETHNA Z, SOARES KC, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer[J]. Nature, 2023, 618( 7963): 144- 150. DOI: 10.1038/s41586-023-06063-y.
    [26]
    NITSCHE U, WENZEL P, SIVEKE JT, et al. Resectability after first-line FOLFIRINOX in initially unresectable locally advanced pancreatic cancer: A single-center experience[J]. Ann Surg Oncol, 2015, 22( Suppl 3): S1212- S1220. DOI: 10.1245/s10434-015-4851-2.
    [27]
    MURPHY JE, WO JY, RYAN DP, et al. Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: A phase 2 clinical trial[J]. JAMA Oncol, 2019, 5( 7): 1020- 1027. DOI: 10.1001/jamaoncol.2019.0892.
    [28]
    HANK T, KLAIBER U, HINZ U, et al. Oncological outcome of conversion surgery after preoperative chemotherapy for metastatic pancreatic cancer[J]. Ann Surg, 2023, 277( 5): e1089- e1098. DOI: 10.1097/SLA.0000000000005481.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (84) PDF downloads(15) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return